Probing tricarbocyanine dyes for targeted delivery of anthracyclines

Dmitry A Veryutin1, Irina A Doroshenko2, Ekaterina A Martynova2

  • 1Lomonosov Moscow State University, Department of Chemistry, Moscow, Russia; Gause Institute of New Antibiotics, Moscow, Russia; Shemyakin-Ovchinnikov Institute of Bioorganic Chemistry, Moscow, Russia.

Biochimie
|September 30, 2022
PubMed

Insights

Researchers created novel drug-dye conjugates for cancer therapy. Hydrophobic dye conjugates showed potent cytotoxicity against HCT116 cancer cells, highlighting the importance of structural features for biological activity.

Area of Science:

  • Medicinal Chemistry
  • Molecular Biology
  • Biotechnology

Background:

  • Heptamethine carbocyanine dyes exhibit near-IR fluorescence and cancer cell affinity.
  • These dyes can serve as fluorescent labels and drug delivery vectors when conjugated with cytotoxic compounds.

Purpose of the Study:

  • To synthesize and evaluate drug-dye dyads of tricarbocyanine dyes and daunorubicin.
  • To investigate the structure-activity relationship of these conjugates for cancer therapy.

Main Methods:

  • Synthesis of four conjugates using Cu-catalyzed Huisgen-Meldal-Sharpless cycloaddition (click reaction).
  • Utilized hydrophilic and hydrophobic heptamethine dyes with varying linkers and daunorubicin derivatives.
  • Evaluated cytotoxicity, cell penetration, intracellular distribution, and apoptosis induction in HCT116 cells.

Main Results:

  • Hydrophobic dye-based conjugates demonstrated submicromolar cytotoxicity against HCT116 cells.
  • Biological activity was significantly influenced by the conjugate's structural properties (hydrophilicity/hydrophobicity, charge, linker, attachment site).

Conclusions:

  • The structural design of cyanine-anthracycline conjugates is critical for their therapeutic efficacy.
  • Expanding the chemical diversity of these conjugates could yield advanced tools for cancer diagnostics and treatment.